197 related articles for article (PubMed ID: 36713431)
1. Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications.
Du P; Li G; Wu L; Huang M
Front Immunol; 2022; 13():1065379. PubMed ID: 36713431
[TBL] [Abstract][Full Text] [Related]
2. The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma.
Hasegawa K; Kato R; Torii Y; Ichikawa R; Oe S; Udagawa Y
Int J Gynecol Cancer; 2011 Nov; 21(8):1479-85. PubMed ID: 21720251
[TBL] [Abstract][Full Text] [Related]
3. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
Zwenger AO; Grosman G; Iturbe J; Leone J; Vallejo CT; Leone JP; Verdera PP; Pérez JE; Leone BA
Int J Biol Markers; 2015 Jul; 30(3):e301-14. PubMed ID: 26165688
[TBL] [Abstract][Full Text] [Related]
4. ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma.
Bai ZL; Wang YY; Zhe H; He JL; Hai P
Radiat Oncol; 2012 Dec; 7():221. PubMed ID: 23259415
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation.
Muallem MZ; Marnitz S; Richter R; Köhler C; Sehouli J; Arsenic R
Anticancer Res; 2014 Jan; 34(1):401-6. PubMed ID: 24403494
[TBL] [Abstract][Full Text] [Related]
6. ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells.
Torii Y; Kato R; Minami Y; Hasegawa K; Fujii T; Udagawa Y
Anticancer Res; 2014 Jan; 34(1):107-15. PubMed ID: 24403450
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of excission repair cross-complementation group one enzyme expression in locally advanced cervical carcinoma patients treated with cisplatin-based treatment: a meta-analysis.
Zhu J; Ji S; Hu Q; Chen Q; Liu Z; Wu J; Gu K
Int J Gynecol Cancer; 2019 Jan; 29(1):35-41. PubMed ID: 30640681
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of DNA repair genes (XRCC1, ERCC1, ERCC2, and ERCC4) in squamous intraepithelial lesion and invasive squamous cell carcinoma of the cervix.
Bajpai D; Banerjee A; Pathak S; Jain SK; Singh N
Mol Cell Biochem; 2013 May; 377(1-2):45-53. PubMed ID: 23435956
[TBL] [Abstract][Full Text] [Related]
9. ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.
Ryu H; Song IC; Choi YS; Yun HJ; Jo DY; Kim JM; Ko YB; Lee HJ
Medicine (Baltimore); 2017 Dec; 96(51):e9402. PubMed ID: 29390553
[TBL] [Abstract][Full Text] [Related]
10. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
[TBL] [Abstract][Full Text] [Related]
11. The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis.
Doll CM; Aquino-Parsons C; Pintilie M; Klimowicz AC; Petrillo SK; Milosevic M; Craighead PS; Clarke B; Lees-Miller SP; Fyles AW; Magliocco AM
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):721-7. PubMed ID: 22836058
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
[TBL] [Abstract][Full Text] [Related]
13. Clinical Perspectives of ERCC1 in Bladder Cancer.
Koutsoukos K; Andrikopoulou A; Dedes N; Zagouri F; Bamias A; Dimopoulos MA
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266377
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 C19007T polymorphism and the risk and invasiveness of cervical cancer in Korean women.
Han SS; Kim JW; Lee SH; Kim DH; Park NH; Song YS; Kang SB
Asia Pac J Clin Oncol; 2012 Dec; 8(4):e63-7. PubMed ID: 22897321
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
Deloia JA; Bhagwat NR; Darcy KM; Strange M; Tian C; Nuttall K; Krivak TC; Niedernhofer LJ
Gynecol Oncol; 2012 Sep; 126(3):448-54. PubMed ID: 22609620
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
[TBL] [Abstract][Full Text] [Related]
17. The roles of excision repair cross-complementation group1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers: a systematic review and meta-analysis.
Gao Y; Liu D
Oral Oncol; 2015 Jun; 51(6):570-7. PubMed ID: 25857670
[TBL] [Abstract][Full Text] [Related]
18. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy.
Wang D; Zhou J; Zheng J; Zhang J; Chen Y; Li W; Wang R
Cancer Biomark; 2018; 21(4):875-881. PubMed ID: 29439312
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer.
de Almeida VH; de Melo AC; Meira DD; Pires AC; Nogueira-Rodrigues A; Pimenta-Inada HK; Alves FG; Moralez G; Thiago LS; Ferreira CG; Sternberg C
Braz J Med Biol Res; 2017 Nov; 51(1):e6822. PubMed ID: 29160417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
